Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bempedoic acid + ezetimibe
- Development stage
- Approved
- Lead developer
- Esperion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bempedoic acid + ezetimibe is a fixed-dose oral combination medication used to lower low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia. It is indicated for use alone or in combination with other LDL-C lowering therapies and as an adjunct to dietary changes. The drug combines two mechanisms of action: - Bempedoic acid inhibits adenosine triphosphate-citrate lyase (ACL), an enzyme involved in hepatic cholesterol synthesis, thereby reducing LDL-C production. - Ezetimibe inhibits the absorption of dietary cholesterol by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine. The combination is also approved to reduce the risk of myocardial infarction and coronary revascularization procedures in adults unable to take recommended statin therapy who have established cardiovascular disease or are at high risk for a cardiovascular event[1][2][3][5][8].
- Brand names
- NexlizetNustendi
- Other names
- bempedoic acid/ezetimibe
02
Targets
ACLY (ATP-citrate synthase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on bempedoic acid + ezetimibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bempedoic acid + ezetimibe.